Crossject : Calendar confirmed for Zepizure
>A very typical results publication for H1 2024 - Crossject reported its Q1 2024 results yesterday. Operating income totalled € 5.8m (vs € 7.9m in 2023), of which € 3.3m came from its regulatory advances with BARDA, slightly up compared to H1 2023 (€ 3.2m). R&D investments remained stable and the operating loss widened marginally (-€ 6.7m vs -€ 6.5m in H1 2023). A classic P&L Regarding the balance sheet, Crossject issued a convertible and/or redeemable bond in t...Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.